Acute kidney injury (AKI) is a sudden episode of kidney failure or damage that occurs within a few hours or days, leading to waste build-up in the blood and improper kidney function. This condition can be caused by several factors such as decreased blood flow to the kidneys, direct damage to the kidneys, or a blockage in the urinary tract. AKI is a significant concern in healthcare, especially in critical care settings, and its incidence is rising worldwide. In 2023, the global acute kidney injury treatment market reached a value of USD 44.23 billion, driven by advancements in treatment options and increasing awareness of the condition. The market is projected to grow at a compound annual growth rate (CAGR) of 6.2% during 2024-2032, reaching USD 76.04 billion by 2032.

1. Market Drivers and Trends

The rising incidence of chronic diseases, particularly diabetes and hypertension, has been one of the key drivers of the acute kidney injury treatment market. These conditions increase the likelihood of kidney damage, particularly among aging populations. As the global population grows older, the number of patients at risk for AKI continues to rise. Furthermore, improvements in diagnostic capabilities have resulted in earlier detection of AKI, further driving the demand for effective treatment solutions.

• Increasing Prevalence of Risk Factors: The prevalence of conditions such as diabetes, cardiovascular diseases, and sepsis, all of which contribute to kidney damage, is rising globally. These diseases can lead to compromised kidney function, eventually causing AKI.
• Technological Advancements in Treatment: Technological improvements in dialysis machines, renal replacement therapies, and medication for kidney support have significantly improved the treatment landscape. As new methods become more accessible, the outcomes of patients with AKI improve, supporting market expansion.
• Rising Awareness and Diagnosis Rates: Awareness campaigns from healthcare organizations and government bodies have increased the early detection of AKI, leading to timely treatment and reducing the risk of chronic kidney disease progression. This rise in early detection is contributing to a growing patient pool in need of treatment.

2. Market Challenges

Despite the positive growth trajectory, the acute kidney injury treatment market faces several challenges:

• High Cost of Treatment: AKI treatment, especially in critical care units, can be expensive, with costs ranging from dialysis to ongoing medications. These high costs can be prohibitive, particularly in low- and middle-income countries, limiting access to advanced treatment options.
• Limited Access to Healthcare in Emerging Markets: Although the market is expanding in developed regions, there remains a gap in access to proper kidney care in emerging markets. Limited healthcare infrastructure and financial constraints prevent many patients from receiving timely and adequate treatment.
• Lack of Skilled Medical Professionals: AKI treatment often requires specialized care from nephrologists and critical care specialists. In regions where there is a shortage of skilled professionals, patient outcomes can be compromised, limiting the overall growth of the market.

Get a Free Sample Report with Table of Contents

3. Market Segmentation

The acute kidney injury treatment market can be segmented based on treatment type, end-user, and region:

• By Treatment Type:
  • Dialysis: Dialysis is one of the primary treatments for AKI, especially in cases where the kidneys have lost significant functionality. Hemodialysis and peritoneal dialysis are commonly used to remove waste and excess fluids from the blood.
  • Medication: Several medications are used to treat underlying causes of AKI or to manage complications. Diuretics, vasodilators, and anti-inflammatory drugs are commonly used.
  • Renal Replacement Therapy (RRT): For critically ill patients, continuous renal replacement therapy (CRRT) is often necessary to stabilize kidney function.
• By End-User:
  • Hospitals: Hospitals remain the largest end-user segment due to the critical nature of AKI treatment, which often requires intensive care.
  • Dialysis Centers: Dialysis centers play a critical role in AKI treatment, particularly for patients with severe kidney damage who require regular dialysis.
  • Homecare Settings: With technological advancements, some patients can now receive dialysis treatments at home, contributing to the growth of this segment.
• By Region:
  • North America: North America holds the largest share of the AKI treatment market, driven by advanced healthcare infrastructure, high awareness, and a large population of patients at risk for AKI.
  • Europe: Europe also holds a significant market share, with the presence of leading healthcare providers and government initiatives aimed at reducing the incidence of kidney-related diseases.
  • Asia Pacific: The Asia Pacific region is expected to witness the fastest growth due to rising healthcare investments and increasing awareness about kidney health.

4. Competitive Landscape

Several key players dominate the global acute kidney injury treatment market. These companies focus on product innovation, strategic partnerships, and expanding their market presence to stay competitive.

4.1. Angion

Angion is a biopharmaceutical company that focuses on organ damage treatments, including acute kidney injury. The company is known for its innovative research in renal care and the development of novel therapies aimed at preventing kidney failure. Their flagship drug, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that aims to accelerate kidney recovery after damage. The success of Angion’s pipeline products could provide groundbreaking advancements in AKI treatment, potentially improving outcomes for critically ill patients.

4.2. AM-Pharma B.V.

AM-Pharma B.V. is another leading player in the AKI treatment market, focusing on therapeutic treatments for inflammatory and kidney diseases. Their main product, recombinant alkaline phosphatase (recAP), is currently in advanced stages of clinical trials for the treatment of AKI. This drug targets inflammation and damage in kidney tissue, aiming to reduce the need for dialysis and improve patient survival rates. AM-Pharma’s innovative approach, combined with strong clinical trial results, positions them as a significant player in the market.

4.3. Baxter International, Inc.

Baxter International, Inc. is a global healthcare company with a significant presence in the AKI treatment space. Baxter is well-known for its dialysis products and renal therapies. The company offers a wide range of hemodialysis and peritoneal dialysis products, including continuous renal replacement therapy (CRRT) solutions for critically ill patients. Baxter’s strong reputation in the renal care market, combined with its extensive distribution network, makes it a leader in providing AKI treatment solutions.

4.4. Fresenius Medical Care Holdings, Inc.

Fresenius Medical Care is one of the world’s largest providers of dialysis services and products. The company plays a pivotal role in AKI treatment, particularly in offering innovative dialysis solutions for patients suffering from kidney injury. Fresenius provides a range of dialysis machines, consumables, and services that cater to both hospital and homecare settings. Their leadership in the dialysis market ensures their ongoing relevance in the treatment of AKI. Fresenius is committed to expanding access to dialysis services and improving patient outcomes worldwide.

5. Future Outlook

The global acute kidney injury treatment market is poised for significant growth over the next decade. Factors such as technological advancements, rising incidence rates of kidney-related diseases, and increased awareness are expected to drive market expansion. However, challenges such as high treatment costs and limited access to healthcare in certain regions could hinder progress.

Innovative approaches from companies like Angion and AM-Pharma B.V. promise to revolutionize AKI treatment by reducing the need for dialysis and improving recovery rates. The global healthcare community’s growing focus on preventive measures and early intervention is also expected to contribute to better outcomes for patients suffering from AKI.